AXQ Capital LP grew its position in Stryker Corporation (NYSE:SYK – Free Report) by 984.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 7,106 shares of the medical technology company’s stock after buying an additional 6,451 shares during the quarter. Stryker comprises 0.6% of AXQ Capital LP’s portfolio, making the stock its 12th biggest position. AXQ Capital LP’s holdings in Stryker were worth $2,498,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the last quarter. Geode Capital Management LLC raised its position in Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Alliancebernstein L.P. raised its position in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Norges Bank bought a new position in Stryker in the 4th quarter worth approximately $1,822,272,000. Finally, Legal & General Group Plc raised its position in Stryker by 2.7% in the 4th quarter. Legal & General Group Plc now owns 2,366,107 shares of the medical technology company’s stock worth $831,616,000 after purchasing an additional 62,817 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.
Insider Activity
In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last quarter. Company insiders own 4.60% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Stock Report on Stryker
Stryker Price Performance
SYK opened at $299.15 on Tuesday. The company has a fifty day moving average price of $321.00 and a two-hundred day moving average price of $347.64. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm has a market capitalization of $114.68 billion, a PE ratio of 34.62, a P/E/G ratio of 1.92 and a beta of 0.80.
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period in the prior year, the firm posted $2.84 EPS. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.
Stryker Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s payout ratio is 40.74%.
About Stryker
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Articles
- Five stocks we like better than Stryker
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
